• Publications
  • Influence
Predicting the course of Gompertzian growth
The development of a generalised approach to the analysis of “Gompertzian” growth which enables accurate predictions of future growth for two model tumour systems is reported.
Growth of human tumor xenografts implanted under the renal capsule of normal immunocompetent mice.
Growth rates of transplantation-established xenograft systems were similar whether implanted in athymic nude or in normal immunocompetent animals indicating that the 6-day time-frame successfully evades growth inhibitory effects of immunologic origin.
Characterization of a human malignant mesothelioma cell line (H-MESO-1): a biphasic solid and ascitic tumor model.
Human malignant mesothelioma of the pleura was successfully transplanted s.c. into athymic nude mice and grew as a solid neoplastic mass and may be of value in animal trials of chemotherapy and immunotherapy.
Variability of hormone concentrations and ratios in commercial sera used for tissue culture.
In vitro and in vivo inhibition of human small cell lung carcinoma (NCI-H69) growth by a somatostatin analogue.
An endocrinologically-potent octapeptide analogue of somatostatin (SRIF), 3-(2-naphthyl)-D-Ala-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH2 (BIM-23014 C), was examined for its ability to inhibit the in vitro
Antitumor activity of intraperitoneal immunotoxins in a nude mouse model of human malignant mesothelioma.
Immunotoxins constructed with ricin A chain have significant tumoricidal activity in this model of regional antitumor therapy and may have direct relevance for treatment of i.p. malignancy in clinical settings.
Chemotherapy responsiveness of human tumors as first transplant generation xenografts in the normal mouse: Six‐day subrenal capsule assay
Feasibility of utilizing human tumors as first transplant generation xenografts in the normal immunocompetent mouse for determining tumor sensitivity to chemotherapeutic agents was demonstrated by
Amelioration of Chemotherapy‐Induced Toxicity by Cotreatment with AcSDKP, a Tetrapeptide Inhibitor of Hematopoietic Stem Cell Proliferation
The stem cell compartment of the bone marrow that guarantees a sufficient supply of cells bound for differentiation, though mainly quiescent, still has approximately 10% of its cellular component in some state of mitosis.
Treatment of R-3327 prostate tumors with a somatostatin analogue (somatuline) as adjuvant therapy following surgical castration.
The relative nontoxicity of a somatostatin analogue such as Somatuline suggests that chronic or maintenance therapy of slow-growing prostate cancers may be both feasible and acceptable in a clinical setting.